With increasing demand and higher costs, ensuring appropriate patient access is more critical than ever and 2025 will likely ...

Ozempic and other similar drugs must be injected. Messer describes the needle as “small, the size of two human hairs.” ...

Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...

Stopping GLP-1 receptor agonists 14 days prior to total hip or knee arthroplasty may reduce several key risk factors ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonist use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use.

Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...

However, for crude incidence rates there was an increased incidence of suicidality with GLP-1 receptor agonist vs DPP-4 inhibitor use; 3.9 vs 1.8 per 1000 person-years. HealthDay News — Glucagon ...

"This finding suggests that it may be beneficial to reassess the preoperative withholding guidelines for GLP-1 RAs." HealthDay News — Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 ...